UA137870U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes a clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (PSP), homocysteine. With homozygous carrier 786-CC, levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies

I.N. Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, according to a useful model, the polymorphism of the nitric oxide synthase gene (6ЕМО5 T7860), the content of thrombomodulin, folic acid, oxyproline, C -reactive protein (SRP), homocysteine and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline "15 μmol/l, SRP "b mg/l, homocysteine 220 μmol/ predict the development of osteoarthritis.

The method is used as follows.

During hospitalization, the patient is examined, x-rays are taken, the polymorphism of the eMmOo5 17860 gene is determined, the content of thrombomodulin, folic acid, oxyproline, SRP, homocysteine is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline "15 μmol/l, SRP "b mg/l, homocysteine "20 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient L., 60 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found.

The eMO5 T786C gene polymorphism and the content of thrombomodulin, folic acid, oxyproline, SRP, and homocysteine were determined in the serum. A homozygous carrier of 786-SS was established, the levels of thrombomodulin - 12 ng/ml, folic acid - 2.8 ng/ml, oxyproline - 28 μmol/l, SRP - 15 mg/l, homocysteine - 32 μmol/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (EEMO5 17860), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein ( SRP), homocysteine, and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "b mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis .